169 related articles for article (PubMed ID: 32695508)
1. ALDH1 Cancer Stem Cell Marker as a Prognostic Factor in Triple-Negative Breast Cancer.
Panigoro SS; Kurnia D; Kurnia A; Haryono SJ; Albar ZA
Int J Surg Oncol; 2020; 2020():7863243. PubMed ID: 32695508
[TBL] [Abstract][Full Text] [Related]
2. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).
Ma F; Li H; Li Y; Ding X; Wang H; Fan Y; Lin C; Qian H; Xu B
Medicine (Baltimore); 2017 Apr; 96(14):e6561. PubMed ID: 28383433
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors.
Yang F; Cao L; Sun Z; Jin J; Fang H; Zhang W; Guan X
Int J Biol Sci; 2016; 12(12):1568-1577. PubMed ID: 27994520
[TBL] [Abstract][Full Text] [Related]
4. Stem cell marker aldehyde dehydrogenase 1 (ALDH1)-expressing cells are enriched in triple-negative breast cancer.
Li H; Ma F; Wang H; Lin C; Fan Y; Zhang X; Qian H; Xu B
Int J Biol Markers; 2013 Dec; 28(4):e357-64. PubMed ID: 24338721
[TBL] [Abstract][Full Text] [Related]
5. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.
Schwartz T; Stark A; Pang J; Awuah B; Kleer CG; Quayson S; Kingman S; Aitpillah F; Abantanga F; Jiagge E; Oppong JK; Osei-Bonsu E; Martin I; Yan X; Toy K; Adjei E; Wicha M; Newman LA
Cancer; 2013 Feb; 119(3):488-94. PubMed ID: 22930220
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of ALDH1A1 expression in early invasive breast cancer.
Althobiti M; El Ansari R; Aleskandarany M; Joseph C; Toss MS; Green AR; Rakha EA
Histopathology; 2020 Sep; 77(3):437-448. PubMed ID: 32369651
[TBL] [Abstract][Full Text] [Related]
7. DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer.
Kurani H; Razavipour SF; Harikumar KB; Dunworth M; Ewald AJ; Nasir A; Pearson G; Van Booven D; Zhou Z; Azzam D; Wahlestedt C; Slingerland J
Clin Cancer Res; 2022 May; 28(9):1948-1965. PubMed ID: 35135840
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.
De Brot M; Rocha RM; Soares FA; Gobbi H
Pathology; 2012 Jun; 44(4):303-12. PubMed ID: 22544210
[TBL] [Abstract][Full Text] [Related]
9. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
Shima H; Kida K; Adachi S; Yamada A; Sugae S; Narui K; Miyagi Y; Nishi M; Ryo A; Murata S; Taniguchi H; Ichikawa Y; Ishikawa T; Endo I
Breast Cancer Res Treat; 2018 Aug; 170(3):507-516. PubMed ID: 29693231
[TBL] [Abstract][Full Text] [Related]
10. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
11. Characterizing Breast Cancer in a Population with Increased Prevalence of Triple-Negative Breast Cancer: Androgen Receptor and ALDH1 Expression in Ghanaian Women.
Proctor E; Kidwell KM; Jiagge E; Bensenhaver J; Awuah B; Gyan K; Toy K; Oppong JK; Kyei I; Aitpillah F; Osei-Bonsu E; Adjei E; Ohene-Yeboah M; Brewer RN; Fondjo LA; Owusu-Afriyie O; Wicha M; Merajver S; Kleer C; Newman L
Ann Surg Oncol; 2015 Nov; 22(12):3831-5. PubMed ID: 25743329
[TBL] [Abstract][Full Text] [Related]
12. Effect of ALDH1 on prognosis and chemoresistance by breast cancer subtype.
Kida K; Ishikawa T; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
Breast Cancer Res Treat; 2016 Apr; 156(2):261-9. PubMed ID: 26975188
[TBL] [Abstract][Full Text] [Related]
13. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
14. GLO 1 and PKCλ Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
Motomura H; Tamori S; Yatani MA; Namiki A; Onaga C; Ozaki A; Takasawa R; Mano Y; Sato T; Hara Y; Sato K; Xiong Y; Harada Y; Hanawa T; Tanuma SI; Sasaki K; Ohno S; Akimoto K
Anticancer Res; 2021 Dec; 41(12):5959-5971. PubMed ID: 34848450
[TBL] [Abstract][Full Text] [Related]
15. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
[TBL] [Abstract][Full Text] [Related]
16. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
17. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
18. Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer.
Mieog JS; de Kruijf EM; Bastiaannet E; Kuppen PJ; Sajet A; de Craen AJ; Smit VT; van de Velde CJ; Liefers GJ
BMC Cancer; 2012 Jan; 12():42. PubMed ID: 22280212
[TBL] [Abstract][Full Text] [Related]
19. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cells in triple-negative breast cancer: a potential target and prognostic marker.
O'Conor CJ; Chen T; González I; Cao D; Peng Y
Biomark Med; 2018 Jul; 12(7):813-820. PubMed ID: 29902924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
